Arthneeti
CS

Chemcon Speciality Chemicals Ltd

Q4 FY26Chemicals & Petrochemicals

Chemcon Speciality Chemicals Q4 FY26: Revenue ₹75.4 Cr, PAT ₹6.4 Cr

Q4 FY26 investor presentation: what the company reported on revenue, margins and projects.

Price₹228
Market cap₹793 Cr
P/E28.1
Updated24 Sept 2026
Read4 min read

Based on Chemcon Speciality Chemicals Ltd's Q4 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

Q4 FY26 Revenue from Operations: ₹75.4 Cr, a 37% YoY increase from ₹54.9 Cr in Q4 FY25. Q4 FY26 Financials (Page 9): - EBITDA: ₹8.9 Cr (54% YoY growth from ₹5.8 Cr in Q4 FY25) - EBITDA Margin: 11.8% (up from 10.5% in Q4 FY25) - Profit After Tax (PAT): ₹6.4 Cr (61% YoY growth from ₹3.9 Cr in Q4 FY25) - PAT Margin: 8.4% (up from 7.2% in Q4 FY25) - Margin Outlook: The presentation does not state any explicit future margin outlook or guidance.

From Chemcon Speciality Chemicals Ltd's Q4 FY26 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

- Q4 FY26 Revenue from Operations: ₹75.4 Cr, a 37% YoY increase from ₹54.9 Cr in Q4 FY25. - Sales Volume for Q4 FY26: 3,497 MT, up from 2,210 MT in Q4 FY25 (organic chemicals 1,972 MT, inorganic chemicals 1,525 MT). - EBITDA for Q4 FY26: ₹8.9 Cr, up 54% YoY. - PAT for Q4 FY26: ₹6.4 Cr, up 61% YoY. - Export contribution rose to 71% in Q4 FY26 from 63% in Q4 FY25. **Outlook:** - Encouraging demand for newer products like Bromobenzene and 2-Bromo.

2 more points management made on revenue & sales performance

Profitability & Margins

See what Chemcon Speciality Chemicals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Capacity Expansion: Commissioned P10 and P11 units adding new manufacturing capacity for organic chemicals (Page 23).
  • New Plant/Project:
  • Proposed P-10 unit expected Q1 FY27 (Page 21).
  • Proposed P-11 unit expected Q1 FY27 (Page 21).
  • Capex Amount: Specific capex amounts are not explicitly stated in the presentation.
  • Status:
  • P10 and P11 units successfully commissioned (Page 23).

2 more points management made on capital expenditure plans

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

5x potential
1Shiv Texchem
Rev 1Mar 2
2Yasho Industries
Rev 1Mar 3
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Chemcon Speciality Chemicals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation does not explicitly mention specific figures or details regarding the company's order book, order inflow, or pending orders. It focuses on: - Financial performance including revenue, EBITDA, and PAT. - Growth drivers such as capacity expansion, new product development, and cost efficiencies. - Operational highlights including commissioning of new manufacturing units.

2 more points management made on order book & pipeline

Chemcon Speciality Chemicals Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹75 Cr, net profit ₹6 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Chemcon Speciality Chemicals Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

  • Vipul Organics Ltd (Q4 FY26)

    Q4 FY26 (Mar 2026) total revenue: ₹5,262.37 lakhs (Consolidated) . Key concall takeaways from Vipul Organics's Q4 FY26 earnings call — and how it ranks against…

  • Chemfab Alkalis Ltd (Q4 FY26)

    Chlor Alkali segment: ₹55.63 crore (down 1.21% YoY from ₹56.31 crore) . Key concall takeaways from Chemfab Alkalis Ltd's Q4 FY26 earnings call — and how it…

  • Sudarshan Pharma Industries Ltd (Q4 FY26)

    Revenue from Operations for Q4 March 2026: ₹220.92 Cr (Page 41) . Key concall takeaways from Sudarshan Pharma Industries Ltd's Q4 FY26 earnings call — and how…

  • Innovassynth Technologies (India) Ltd (Q4 FY26)

    Order book improved by approximately INR 60 crore during the quarter, indicating strong customer demand and revenue visibility. Key concall takeaways from…

Compare:vs Solar Industriesvs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Chemcon Speciality Chemicals Ltd Q4 FY26 results?

Q4 FY26 Revenue from Operations: ₹75.4 Cr, a 37% YoY increase from ₹54.9 Cr in Q4 FY25. Q4 FY26 Financials (Page 9): - EBITDA: ₹8.9 Cr (54% YoY growth from ₹5.8 Cr in Q4 FY25) - EBITDA Margin: 11.8% (up from 10.5% in Q4 FY25) - Profit After Tax (PAT): ₹6.4 Cr (61% YoY growth from ₹3.9 Cr in Q4 FY25) - PAT Margin: 8.4% (up from 7.2% in Q4 FY25) - Margin Outlook: The presentation does not state any explicit future margin outlook or guidance.

What is Chemcon Speciality Chemicals Ltd share price analysis?

Chemcon Speciality Chemicals Ltd currently shows a neutral. The stock trades at a P/E of 28.1 with a market cap of ₹793 Cr. Investors should review the full earnings analysis for detailed insights.

Is Chemcon Speciality Chemicals Ltd planning capital expenditure?

Capacity Expansion: Commissioned P10 and P11 units adding new manufacturing capacity for organic chemicals (Page 23).

Keep Chemcon Speciality Chemicals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.